COLORECTAL CANCER

Colorectal Cancer

Understanding colon and rectal cancer, from screening and diagnosis to treatment and living well.

A guide for patients and families. The location, stage and biological features of the cancer help shape the right questions for your healthcare team.

Colon and rectal cancer: related, but not identical

Colorectal cancer starts in the large bowel: the colon or the rectum, the final section before the anus. Most are adenocarcinomas, arising from the bowel lining. Some develop from polyps over years; not every polyp becomes cancer. Removing precancerous polyps can prevent some cancers.

Colon cancer

Surgery is usually the main treatment for localised disease. The surgical pathology helps determine whether chemotherapy is useful afterwards. Radiotherapy is not routinely used.

Rectal cancer

The confined pelvis and closeness to the anal sphincter make local staging and treatment planning especially important. Pelvic MRI, treatment before surgery and discussion of bowel function are often central to care.

Anal cancer is a different disease with a different treatment pathway. Cancer that spreads from the bowel to the liver or lung is still colorectal cancer, not a new primary liver or lung cancer.

Risk factors and prevention

Risk increases with age, but younger adults can also develop colorectal cancer. A risk factor does not mean that cancer is inevitable, and some people have no obvious risk factor.

  • A personal history of colorectal cancer or certain polyps
  • A close relative with colorectal cancer, particularly at a young age, or multiple affected relatives
  • Inherited conditions such as Lynch syndrome, familial adenomatous polyposis (FAP) and other polyposis syndromes
  • Long-standing ulcerative colitis or Crohn’s disease affecting the colon; these differ from irritable bowel syndrome
  • Smoking, excess alcohol, excess body weight, physical inactivity and diets high in processed meat

Regular activity, a healthy weight, avoiding tobacco, limiting alcohol and choosing whole grains, vegetables, fruit and other fibre-rich foods support prevention. Limit processed meat and excess red meat. Screening and appropriate polyp removal are important even with a healthy lifestyle.

Do not start aspirin or supplements solely to prevent cancer without medical advice. Benefits and bleeding risks depend on the individual; aspirin may be discussed in selected hereditary-risk settings. See prevention.

Symptoms and warning signs

  • Blood in or on the stool, rectal bleeding, or persistent dark stools
  • A persistent change in bowel habit, including diarrhoea, constipation or a feeling of incomplete emptying
  • Unexplained iron-deficiency anaemia, tiredness or breathlessness
  • Persistent abdominal discomfort, cramping, bloating or a lump
  • Unintentional weight loss or loss of appetite

These symptoms can have non-cancer causes. Bleeding should not automatically be labelled as piles, especially when persistent, recurrent or accompanied by anaemia. Early cancer may cause no symptoms. Seek assessment for concerning symptoms at any age; do not wait until you qualify for screening.

See warning signs and the urgent symptoms below.

Screening: FIT, stool tests and colonoscopy

Screening is for people without symptoms. It can detect cancer earlier and identify precancerous polyps. Investigation of symptoms is a diagnostic assessment, even if a screening test was recently normal.

As a labelled international reference, the American Cancer Society recommends starting average-risk screening at 45 years. It generally continues through 75 in people in good health with more than 10 years’ life expectancy; ages 76–85 require individual decisions. This is a US recommendation, not a universal Indian national programme. Discuss locally available tests, personal risk, health and previous screening with your clinician.

FIT and other stool tests

FIT (faecal immunochemical testing) looks for hidden blood in a stool sample. Annual FIT is one common screening option. Other options include high-sensitivity guaiac testing and combined stool DNA tests, with intervals depending on the test and programme.

A positive result does not prove cancer, but needs timely colonoscopy. Repeating FIT to obtain a negative result is not a substitute. A negative result cannot exclude every cancer, particularly in someone with symptoms.

Colonoscopy

A flexible camera examines the colon and rectum. Polyps can often be removed and abnormal areas biopsied during the procedure. Bowel preparation is essential; sedation may be offered. Bleeding, perforation and sedation complications are uncommon but important risks to discuss.

After a normal, high-quality examination, 10 years is a common average-risk screening interval. Polyps, inadequate preparation, symptoms or inherited risk can require earlier reassessment.

People with significant family history, hereditary syndromes or inflammatory bowel disease may need earlier and more frequent colonoscopy. The starting age depends on the exact risk. CT colonography and flexible sigmoidoscopy are alternatives in some programmes; abnormal findings may still need colonoscopy. Screening blood tests have different limitations and do not replace diagnostic investigation of symptoms.

See the Cancer Aware screening guide.

Diagnosis, biopsy and pathology

Assessment usually combines the history, examination, blood tests and colonoscopy with biopsy. For a rectal lesion, a digital rectal examination helps assess its position. If a narrowed bowel prevents complete colonoscopy, the team plans how and when to evaluate the remaining colon safely.

A biopsy allows a pathologist to identify cancer and its type. A CT scan can show a suspicious mass but usually cannot replace tissue diagnosis. Tests may include a blood count, iron studies and kidney and liver function. CT of the chest, abdomen and pelvis assesses spread; pelvic MRI is important for rectal cancer, and liver MRI can clarify liver lesions. PET-CT is useful selectively, not routinely required for every patient.

What does the pathology report tell you?

  • Histological type and grade: what the cells look like
  • Depth of invasion and whether the tumour reaches nearby structures
  • Margins: whether cancer is present at the cut edges
  • Number of lymph nodes examined and involved, plus tumour deposits where present
  • Lymphovascular or perineural invasion: cancer in small vessels or around nerves
  • For rectal cancer, the circumferential margin and response to preoperative treatment
  • MMR/MSI results and other relevant molecular findings

At least 12 examined nodes is a common quality benchmark after colon resection, although individual circumstances, including prior treatment, affect interpretation. Grade is not the same as stage. Ask for copies of the pathology, operation report and molecular results. See Understanding Your Cancer Diagnosis.

Understanding TNM and stage

T describes how deeply the tumour invades the bowel wall and nearby structures, N describes regional lymph-node involvement, and M describes distant spread. Tumour size alone does not determine the T category in colorectal cancer.

  • Stage 0: abnormal cancer cells confined to the innermost lining.
  • Stage I: growth into the bowel wall without regional lymph-node or distant spread.
  • Stage II: growth through the muscle layer into outer tissues or nearby organs, without regional lymph-node involvement or distant metastases.
  • Stage III: regional lymph-node involvement or qualifying tumour deposits, without distant metastases.
  • Stage IV: spread to distant organs or the peritoneum, the lining of the abdomen.

The clinical stage is estimated before treatment. The pathological stage comes from tissue removed at surgery. After preoperative treatment, a “yp” stage describes the remaining cancer; it must be interpreted alongside the original stage and treatment response. Rectal MRI also assesses features such as threatened surgical margins that can change treatment even within the same broad stage.

CEA: helpful for monitoring, not a screening test

Carcinoembryonic antigen (CEA) is a blood tumour marker that may be checked at diagnosis and during treatment or follow-up. Trends can help the team decide whether further assessment is needed.

CEA cannot diagnose or exclude colorectal cancer by itself. Some cancers never produce a high CEA, and smoking or non-cancer conditions may raise it. One abnormal result does not establish recurrence. Interpret it with symptoms, examination and imaging; CEA is not a substitute for colonoscopy or an appropriate population screening test.

MMR/MSI and molecular testing

Biomarkers help identify treatments more likely to work. Testing the tumour is different from testing for an inherited condition. Ask which results are available before a major treatment decision.

MMR / MSI
Colorectal cancers should be assessed for mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). These related tests identify problems in DNA repair. They inform immunotherapy, some adjuvant decisions and assessment for Lynch syndrome. pMMR/MSS means repair appears proficient or the tumour is microsatellite stable.
KRAS and NRAS
In metastatic disease, extended RAS testing helps assess suitability for EGFR-targeted antibodies. RAS mutations generally predict lack of benefit from conventional cetuximab or panitumumab regimens. “Wild-type” means the tested mutations were not found; it does not guarantee response.
BRAF V600E
This specific alteration can affect prognosis and open a BRAF-targeted combination pathway. BRAF inhibitors are generally combined with EGFR blockade in colorectal cancer, sometimes with chemotherapy, according to the setting and local approvals.
HER2
HER2 amplification or strong overexpression can identify selected advanced cancers for HER2-directed therapy. The exact test result, RAS status, previous treatment and eligibility matter; not every HER2 change means the same thing.
NTRK and uncommon targets
Rare NTRK fusions can support TRK-targeted treatment. RET fusions and specific KRAS G12C mutations may also offer options in selected advanced cancers. KRAS G12C treatment may combine a KRAS inhibitor with an EGFR antibody; this is a specific exception, not a treatment for all RAS-mutant tumours.

Broader next-generation sequencing (NGS) can test multiple genes together in advanced disease and identify clinical-trial options. Some findings have no proven treatment, and a result labelled “uncertain significance” is not a reason to prescribe a targeted drug.

Blood-based tumour DNA profiling may help when tissue is unavailable or results are needed quickly. A negative blood result may miss an alteration because some tumours release little DNA; tissue testing may still be needed. PD-L1 is not the usual biomarker used to select immunotherapy in colorectal cancer. See Cancer Biomarkers & Precision Oncology.

Lynch syndrome and inherited risk

Most colorectal cancers are not caused by a recognised inherited syndrome. Lynch syndrome involves inherited changes in DNA mismatch-repair genes or EPCAM and increases the risk of colorectal, endometrial and several other cancers.

An abnormal tumour MMR/MSI result does not automatically mean Lynch syndrome. For example, loss of MLH1/PMS2 may lead to MLH1 promoter methylation and/or BRAF testing to help distinguish a sporadic tumour from inherited risk. Genetic counselling and, when appropriate, germline testing clarify the result.

Diagnosis at a young age, multiple related cancers in a family or numerous polyps warrant hereditary-risk assessment even when initial tumour testing is reassuring. FAP, MUTYH-associated polyposis and other syndromes have different surveillance plans. If an inherited pathogenic variant is found, relatives can be offered targeted testing and prevention advice. A negative or uncertain test needs interpretation in the context of the family history.

ctDNA and minimal residual disease: an evolving area

Circulating tumour DNA (ctDNA) is DNA shed by cancer into blood. After apparently curative treatment, detecting it may suggest molecular or minimal residual disease (MRD) and a higher recurrence risk, even before a scan shows cancer.

Predicting risk is not the same as proving that changing treatment improves outcomes. Results depend on the assay, timing and tumour shedding. A negative test does not prove cure, and a positive result does not locate disease.

Do not use ctDNA alone to omit, intensify or stop standard treatment or follow-up. Its use to guide postoperative treatment remains an evolving, specialist-led area, preferably within validated pathways or clinical trials. It does not replace imaging, colonoscopy, clinical assessment or established pathology-based decisions.

Treatment of localised colon cancer

A multidisciplinary team considers stage, pathology, MMR/MSI, general fitness, other illnesses and the patient’s priorities. The goal is often cure, but benefit and risk vary.

Surgery

Some very early cancers within a polyp can be completely treated endoscopically if removal and pathology meet strict criteria. Otherwise, surgery usually removes the affected bowel segment and its draining lymph nodes. The remaining ends may be joined. A temporary or permanent stoma is needed in some situations, especially emergencies; it is not inevitable for everyone.

Adjuvant treatment after surgery

  • Stage I: surgery is usually sufficient.
  • Stage II: chemotherapy is not automatic. T4 disease, obstruction or perforation, inadequate nodal assessment and other adverse pathology features can increase risk. MMR/MSI and likely absolute benefit guide discussion. Fluoropyrimidine alone is generally not offered routinely for dMMR/MSI-H stage II disease; high-risk cases need individual consideration.
  • Stage III: chemotherapy is usually recommended for suitable patients, commonly FOLFOX or CAPOX. These combine a fluoropyrimidine with oxaliplatin. A shorter or longer course, often around three or six months, depends on nodal and tumour risk, regimen, neuropathy risk and fitness.

Older age alone should not decide eligibility. Kidney function, frailty, recovery, other illnesses and preferences matter. Selected locally advanced colon cancers may receive treatment before surgery after specialist assessment. Biomarker-led perioperative approaches are evolving; the team should check current guidance and local access. Radiotherapy is not a standard component for most resected colon cancers.

Rectal cancer: treatment before surgery and organ preservation

Early rectal cancers may be treated with local excision in carefully selected cases or formal rectal surgery. For locally advanced disease, pelvic MRI and a specialist team guide treatment according to tumour height, margins, nodal disease, MMR/MSI and risk of local or distant relapse.

Neoadjuvant therapy and TNT

Neoadjuvant treatment is given before surgery. Total neoadjuvant therapy (TNT) delivers chemotherapy and pelvic radiation-based treatment before the planned operation, especially for lower or higher-risk pMMR/MSS rectal cancers. Its sequence and radiation schedule vary. Some lower-risk patients may follow other pathways, including selective omission of radiation under established criteria.

Radiotherapy may be given as a short course or as a longer course with a radiosensitising drug such as capecitabine or 5-FU. It helps local control but can affect bowel, urinary and sexual function and fertility. Discuss fertility preservation before treatment where relevant.

Surgery and bowel function

Total mesorectal excision removes the rectum and surrounding tissue containing lymph nodes. Whether the anus can be preserved depends on tumour position, safe margins and function. Some patients need a temporary ileostomy or permanent colostomy. A stoma nurse can explain practical care. Frequent or urgent stools, clustering and leakage after low rectal surgery are known as low anterior resection syndrome and deserve active support.

Watch-and-wait after a complete clinical response

Some patients with no detectable residual tumour on expert examination, endoscopy and MRI after treatment may discuss a structured non-operative watch-and-wait programme. A complete clinical response is not the same as proof that every cancer cell is gone.

This requires informed choice, an experienced team and frequent surveillance, especially early on. Local regrowth can occur; prompt salvage surgery may be needed. Simply feeling better, a normal CEA or a negative biopsy alone does not establish eligibility. Watch-and-wait is not an option to skip follow-up.

dMMR/MSI-H rectal cancer

Immunotherapy can be an initial option for locally advanced dMMR/MSI-H rectal cancer within specialist pathways. Major responses may allow discussion of organ preservation, but careful response assessment and ongoing surveillance remain essential. This does not apply to most pMMR/MSS rectal cancers, and no outcome is guaranteed.

Metastatic colorectal cancer

Stage IV disease is diverse. Treatment may aim to control cancer, relieve symptoms and prolong life. In selected people with limited metastases that can all be removed or ablated, a multidisciplinary plan may have curative intent.

Chemotherapy and treatment intensity

Common options include FOLFOX or CAPOX, using oxaliplatin, and FOLFIRI, using irinotecan. Selected fit patients may receive a more intensive combination such as FOLFOXIRI. Others benefit from gentler treatment. Maintenance, breaks and later-line options are personalised according to response, side effects, prior drugs and goals.

Targeted therapy and tumour sidedness

VEGF-directed drugs such as bevacizumab may accompany chemotherapy. For suitable RAS wild-type, usually BRAF wild-type, left-sided tumours, an EGFR antibody with chemotherapy is often considered. Right-sided origin generally makes an EGFR-based first-line approach less favourable; sidedness is one factor alongside biomarkers and treatment goals, not a rule that no treatment can work.

BRAF V600E, HER2 and rare alterations may support matched therapy, as explained in molecular testing. Drug combinations, sequencing, approvals and access vary by country and change over time. A molecular finding does not by itself establish eligibility.

Immunotherapy

For MSI-H/dMMR advanced colorectal cancer, checkpoint immunotherapy is an important option, often early in treatment. Examples include pembrolizumab and nivolumab-based treatment. It does not help everyone and can cause immune inflammation in organs such as the bowel, liver, lungs and hormone glands. Most MSS/pMMR colorectal cancers do not routinely benefit from checkpoint immunotherapy alone; exceptions and trials need expert assessment.

Liver, lung and peritoneal metastases

Request multidisciplinary review when disease may be removable or treatable with ablation or stereotactic radiotherapy. This may involve a colorectal surgeon, liver or thoracic surgeon, radiologist, radiation oncologist and medical oncologist. Feasibility depends on sites, distribution, biology, remaining organ function and fitness, not just the number of spots.

Systemic treatment can sometimes make initially unresectable disease suitable for local treatment, so reassessment matters. Peritoneal disease needs specialist evaluation; major cytoreductive surgery and intraperitoneal treatments are not routine for everyone. Removing an asymptomatic primary tumour is not automatically helpful when distant disease cannot be eradicated, but bleeding, obstruction or perforation may require intervention.

Response, follow-up and recurrence

During treatment, symptoms, examination, blood tests and scheduled scans assess benefit and safety. CEA is useful when informative at baseline but cannot replace imaging. Stable disease can represent meaningful control in advanced cancer. A clear scan or normal marker does not prove that microscopic disease is absent.

After treatment with curative intent, follow-up is tailored to stage, recurrence risk, previous treatment and fitness for further treatment. It commonly includes clinical visits, CEA where appropriate, CT imaging and colonoscopy. A colonoscopy is often planned around one year after surgery, with earlier evaluation if the colon was not fully examined before surgery; subsequent timing depends on findings.

Rectal organ-preservation programmes require a separate, more intensive schedule with rectal examination, endoscopy and MRI. Keep a written surveillance plan and report new persistent symptoms between visits.

Recurrence may be local or distant. Further scans, sometimes biopsy and updated molecular testing help plan treatment. Selected recurrences remain amenable to surgery or ablation; others are treated with systemic therapy and symptom-directed care. Recurrence does not mean the patient caused the cancer or failed their treatment.

Supportive care, daily life and prognosis

Supportive and palliative care can start alongside active cancer treatment. They help with pain, nausea, fatigue, bowel problems, nutrition, sleep, anxiety and family needs; palliative care does not mean giving up.

  • Ask for dietitian support for weight loss, poor intake, dehydration or stoma-related problems. Avoid restrictive “anti-cancer” diets.
  • Report diarrhoea, mouth sores, hand-foot soreness and tingling or numbness early. Oxaliplatin neuropathy can become persistent.
  • Discuss blood-count monitoring and infection precautions. Before 5-FU or capecitabine, ask about DPD deficiency testing according to local practice, as deficiency can cause severe toxicity.
  • Targeted drugs can affect skin, blood pressure, wound healing or bleeding; immunotherapy can cause delayed immune side effects. Get a written drug-specific contact plan.
  • Seek stoma support, rehabilitation, sexual-health and fertility advice, psychological support and help with financial or travel burdens.

Prognosis depends on stage, tumour biology, whether all disease can be treated locally, general health and response to treatment. Many early cancers are treated with curative intent; advanced cancer may be controlled for meaningful periods, and selected metastatic disease may also be approached with curative intent. Population survival figures cannot predict an individual’s outcome. Ask about realistic goals, uncertainty and what would change the plan.

See Cancer Treatment Explained.

Questions for your oncology team

  1. Is this colon or rectal cancer, and what is the exact type and stage?
  2. Has my case been discussed by a multidisciplinary team?
  3. What do my margins, lymph nodes and other pathology risk features show?
  4. What are my MMR/MSI results? Do I need genetic counselling?
  5. If disease is advanced, are RAS, BRAF, HER2 and broader molecular results available?
  6. Is the treatment goal cure, reducing recurrence risk, disease control or symptom relief?
  7. Why is this sequence of surgery, chemotherapy, radiation or immunotherapy appropriate?
  8. Could liver or lung metastases be removed or ablated?
  9. Will I need a stoma? What bowel, urinary, sexual or fertility effects should I expect?
  10. If watch-and-wait is considered, how was complete response assessed and what is the surveillance plan?
  11. What benefit, side effects, costs, alternatives and clinical trials should I consider?
  12. Who do I contact urgently, including at night, and what follow-up is planned?

Myths and facts

  • “Only older people get bowel cancer.” Younger adults can develop it; symptoms need assessment at any age.
  • “Bleeding is always piles.” Piles are common, but persistent bleeding still needs assessment.
  • “No symptoms means screening is unnecessary.” Screening is intended for people without symptoms.
  • “A normal FIT or CEA rules out cancer.” Neither can reliably exclude cancer in a symptomatic person.
  • “Everyone needs a permanent stoma.” Many do not; the answer depends on the operation and circumstances.
  • “A complete response means follow-up can stop.” Surveillance remains essential, especially with organ preservation.
  • “Stage IV means nothing can be done.” Systemic treatment, selected local treatments and supportive care can all have important roles.
  • “A special diet or supplement can replace treatment.” No such replacement is proven; some supplements interact with cancer medicines.

Explore more cancer myths and facts.

When to seek urgent medical help

  • Severe or worsening abdominal pain, a swollen abdomen, repeated vomiting, or inability to pass stool or gas: possible bowel obstruction or perforation
  • Heavy rectal bleeding, black stools with weakness, fainting or marked breathlessness
  • Fever of 38°C or more during chemotherapy, shaking chills or suddenly feeling very unwell; follow any stricter threshold given by your team
  • Severe diarrhoea, inability to drink, very little urine, or a suddenly high-output stoma with dizziness
  • New chest pain, sudden breathlessness, or a painful swollen leg
  • New severe diarrhoea, breathlessness, jaundice or confusion during or after immunotherapy

Seek emergency care for severe symptoms. Do not wait for a routine appointment or an online reply. Contact your oncology team promptly for other new or worsening treatment effects.

Sources & Medical Review

This guide synthesises patient information and professional guidance from the resources below. Recommendations and drug availability vary by country and evolve over time. Mention of an organisation does not imply endorsement.

Sources checked and educational content updated: .

Medical Content & Review

Dr Hakeem Ansar Hussain

Medical Oncologist

Last medically reviewed: Not yet recorded

Medical Disclaimer

This page provides general education, not an individual diagnosis, treatment recommendation or prescription. Discuss symptoms, test results and treatment choices with your own qualified healthcare team. Do not start, stop or change treatment based on this page. For severe or urgent symptoms, seek immediate medical care.